AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35595003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretomanid (PK analysis, n = 46)
Number of subjects: 60
Study 32512575 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO stents with anti-stent migration system
Number of subjects: 12
Study 32702837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sihogayonggolmoryeo-tang (SYM) granules administered twice a day for 4 weeks
Number of subjects: 30
Study 32702837 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (no SYM granules)
Number of subjects: 30
Study 35688623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose chest CT (ULDCT)
Number of subjects: 2418
Study 35688623 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 2418
Study 32524512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin/nab-paclitaxel
Number of subjects: 0
Study 32524512 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/nab-paclitaxel alone
Number of subjects: 0
Study 36411151 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bTsMS
Number of subjects: 26
Study 36411151 — intervention group
Group type: COMPARATOR
Intervention: Sham bTsMS
Number of subjects: 26
Study 34173816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilex paraguariensis leaf infusion
Number of subjects: 14
Study 34173816 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14
Study 32187469 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiskectomy
Number of subjects: 128
Study 32187469 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical care
Number of subjects: 128
Study 35963802 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg (Japanese group)
Number of subjects: 27
Study 35963802 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg (Non-Japanese group)
Number of subjects: 27
Study 35963802 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran (all doses)
Number of subjects: 27
Study 32591310 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve Bayes (NB) model
Number of subjects: 849
Study 32591310 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression
Number of subjects: 849
Study 32591310 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network
Number of subjects: 849
Study 32591310 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest
Number of subjects: 849
Study 32591310 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-vector machine
Number of subjects: 849
Study 34518264 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab maintenance dosing every 8 weeks (q8w)
Number of subjects: 0
Study 34518264 — intervention group
Group type: COMPARATOR
Intervention: guselkumab investigational maintenance dosing every 16 weeks (q16w)
Number of subjects: 0
Study 35536044 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT (antimicrobial photodynamic therapy)
Number of subjects: 46
Study 35536044 — intervention group
Group type: COMPARATOR
Intervention: OFD (open flap debridement)
Number of subjects: 46
Study 33664155 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based intervention (MI)
Number of subjects: 0
Study 33664155 — intervention group
Group type: COMPARATOR
Intervention: Non-music control intervention
Number of subjects: 0
Study 36052904 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-wire fixation and closure (study group)
Number of subjects: 293
Study 36052904 — intervention group
Group type: COMPARATOR
Intervention: Single-wire fixation and closure (control group)
Number of subjects: 293
Study 32462958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (maximum treatment duration of 2 years)
Number of subjects: 0
Study 32462958 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (platinum doublet)
Number of subjects: 0
Study 616830555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (30 mg of lycopene) consumed daily for 12 weeks
Number of subjects: 44
Study 616830555 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant capsule (vitamin C 600 mg, vitamin E 200 mg, glutathione 300 mg) consumed daily for 12 weeks
Number of subjects: 44
Study 616830555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 34840294 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol foam sclerotherapy
Number of subjects: 120
Study 34840294 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 120
Study 32242764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine
Number of subjects: 57
Study 32242764 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 57
Study 34024559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethiopian body fat percent (BF%) prediction equation
Number of subjects: 704
Study 34024559 — intervention group
Group type: COMPARATOR
Intervention: Caucasian body fat percent (BF%) prediction equation
Number of subjects: 704
Study 33069302 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual community-wide mass drug administration (MDA) for soil-transmitted helminthiasis
Number of subjects: 36327
Study 35977854 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Recombinant Human Nerve Growth Factor (rhNGF)
Number of subjects: 0
Study 35977854 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 33596674 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for anterior circulation large vessel occlusion
Number of subjects: 1793
Study 33596674 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for posterior circulation large vessel occlusion
Number of subjects: 1793
Study 33596674 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for anterior circulation with underlying intracranial atherosclerotic disease
Number of subjects: 1793
Study 33596674 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for anterior circulation
Number of subjects: 1793
Study 32130376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of essential balm, vinegar, alcohol, and rose perfume for olfactory training
Number of subjects: 125
Study 32130376 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 125
Study 33686804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 18
Study 34101740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program aimed at promoting healthy eating habits
Number of subjects: 823
Study 35226526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic subcutaneous scopolamine butylbromide
Number of subjects: 0
Study 35226526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32462935 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement strategies designed to boost academic success and persistence during the 6-month learning and development (L&D) phase of the program.
Number of subjects: 317
Study 33513060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis with Elkins Hypnotizability Scale (EHS) induction
Number of subjects: 55
Study 33513060 — intervention group
Group type: COMPARATOR
Intervention: Self-hypnosis with Elkins Hypnotizability Scale (EHS) induction and audio recording
Number of subjects: 55
Study 32610358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) use, n=44, average of 200 minutes/week, starting 1 week postoperative and continuing through week 12.
Number of subjects: 66
Study 32610358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) use, n=44.
Number of subjects: 66
Study 32610358 — intervention group
Group type: COMPARATOR
Intervention: No NMES, n=22 (control group).
Number of subjects: 66
Study 33650729 — intervention group
Group type: EXPERIMENTAL
Intervention: Active expiratory muscle strength training for 4 weeks
Number of subjects: 50
Study 33650729 — intervention group
Group type: COMPARATOR
Intervention: Sham handheld device
Number of subjects: 50
Study 33137572 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voltage-based algorithm for detecting PGES
Number of subjects: 0
Study 34108187 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention (viewing a digital narrative and responding to a writing prompt)
Number of subjects: 215
Study 34108187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 215
Study 34108187 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 215
Study 34956218 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats (80 g daily for 45 days)
Number of subjects: 210
Study 34956218 — intervention group
Group type: COMPARATOR
Intervention: Rice (80 g daily for 45 days)
Number of subjects: 210
Study 35633327 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol treatment with a course of hepatoprotector for one month
Number of subjects: 57
Study 35633327 — intervention group
Group type: COMPARATOR
Intervention: Protocol treatment without hepatoprotector
Number of subjects: 57
Study 33556319 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda 180 µg
Number of subjects: 60
Study 33556319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32333570 — intervention group
Group type: COMPARATOR
Intervention: tDCS at 0 μA
Number of subjects: 0
Study 32333570 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS at 500 μA
Number of subjects: 0
Study 32333570 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS at 1,000 μA
Number of subjects: 0
Study 32333570 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS at 1,500 μA
Number of subjects: 0
Study 32333570 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS at 2,000 μA
Number of subjects: 0
Study 32333570 — intervention group
Group type: COMPARATOR
Intervention: Non-stimulation condition
Number of subjects: 0
Study 36303075 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-based follow-up care
Number of subjects: 402
Study 36303075 — intervention group
Group type: COMPARATOR
Intervention: Primary care-based follow-up care
Number of subjects: 402
Study 33504893 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients
Number of subjects: 60
Study 33504893 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 34904225 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG-Ida
Number of subjects: 115
Study 34904225 — intervention group
Group type: COMPARATOR
Intervention: DA/ADE
Number of subjects: 115
Study 32151443 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffolds (BRS)
Number of subjects: 1614
Study 35611568 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated central retinal laser and 2.0 mg aflibercept
Number of subjects: 41
Study 35611568 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept monotherapy
Number of subjects: 41
Study 33096545 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading group (10 headers with soccer balls projected at 25 mph)
Number of subjects: 68
Study 33096545 — intervention group
Group type: COMPARATOR
Intervention: Kicking-control group (10 kicks)
Number of subjects: 68
Study 33096545 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading group
Number of subjects: 68
Study 33096545 — intervention group
Group type: COMPARATOR
Intervention: Kicking-control group
Number of subjects: 68
Study 36441776 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal irreversible electroporation
Number of subjects: 106
Study 36441776 — intervention group
Group type: COMPARATOR
Intervention: Extended irreversible electroporation
Number of subjects: 106
Study 33647718 — intervention group
Group type: EXPERIMENTAL
Intervention: GNAstV infection (0.5 mL GNAstV‐JSHA intramuscularly)
Number of subjects: 40
Study 33647718 — intervention group
Group type: COMPARATOR
Intervention: Negative control (PBS inoculation)
Number of subjects: 40
Study 32683658 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine transgluteal approach (Group A)
Number of subjects: 240
Study 32683658 — intervention group
Group type: COMPARATOR
Intervention: Modified prone approach (Group B)
Number of subjects: 240
Study 32683658 — intervention group
Group type: COMPARATOR
Intervention: Prone position approach (Group C)
Number of subjects: 240
Study 33059389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based teasing (WBT)
Number of subjects: 312
Study 32916132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (2 capsules of 4 mg) administered orally 1 hour before dental extraction
Number of subjects: 93
Study 32916132 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules with same characteristics as dexamethasone) administered orally 1 hour before dental extraction
Number of subjects: 93
Study 33879223 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhigancao Tang granules
Number of subjects: 122
Study 33879223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 33293284 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staging (transperitoneal laparoscopy)
Number of subjects: 255
Study 33293284 — intervention group
Group type: COMPARATOR
Intervention: Clinical staging
Number of subjects: 255
Study 35535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingernail As concentration
Number of subjects: 658
Study 35535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingernail Pb concentration
Number of subjects: 658
Study 35535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingernail Hg concentration
Number of subjects: 658
Study 35535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Se concentration
Number of subjects: 658
Study 35535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicant concentrations (As, Pb, Hg)
Number of subjects: 658
Study 35535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Se status
Number of subjects: 658
Study 33724251 — intervention group
Group type: COMPARATOR
Intervention: Dasotraline 4 mg/day
Number of subjects: 0
Study 33724251 — intervention group
Group type: COMPARATOR
Intervention: Dasotraline 6 mg/day
Number of subjects: 0
Study 33724251 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 32980184 — intervention group
Group type: EXPERIMENTAL
Intervention: LC28-0126 (3, 10, 20, or 30 mg doses, infused over 30 min, once daily for 7 days)
Number of subjects: 32
Study 32980184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive control vehicle, infused over 30 min, once daily for 7 days)
Number of subjects: 32
Study 35429465 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month oral itraconazole
Number of subjects: 164
Study 35429465 — intervention group
Group type: COMPARATOR
Intervention: 6-month oral itraconazole
Number of subjects: 164
Study 33568388 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO‐LR model for SLE diagnosis
Number of subjects: 802
Study 33568388 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO‐LR model for early disease
Number of subjects: 802
Study 33568388 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO‐LR model for nephritis
Number of subjects: 802
Study 33568388 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO‐LR model for neuropsychiatric lupus
Number of subjects: 802
Study 33568388 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO‐LR model for severe lupus requiring immunosuppressives/biologics
Number of subjects: 802
Study 33568388 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system based on LASSO‐LR model
Number of subjects: 802
Study 32160661 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy (target Pao2, 55 to 70 mm Hg; Spo2, 88 to 92%)
Number of subjects: 205
Study 32160661 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen therapy (target Pao2, 90 to 105 mm Hg; Spo2, ≥96%)
Number of subjects: 205
Study 32160661 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 205
Study 33548070 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-funded trials
Number of subjects: 83
Study 33548070 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic/clinical authors
Number of subjects: 83
Study 33548070 — intervention group
Group type: EXPERIMENTAL
Intervention: Payments >$10,000
Number of subjects: 83
Study 33018534 — intervention group
Group type: EXPERIMENTAL
Intervention: Active RAVANS at 25 Hz
Number of subjects: 20
Study 33018534 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 35470103 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiliency in Stressful Experiences (RISE) program
Number of subjects: 400
Study 35470103 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 400
Study 33871595 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BOTOX Cosmetic) treatment
Number of subjects: 45
Study 33871595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 45
Study 32209605 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (ECV+)
Number of subjects: 2058
Study 32209605 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (ECV-)
Number of subjects: 2058
Study 34699671 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid after dermapen microneedling
Number of subjects: 20
Study 34699671 — intervention group
Group type: COMPARATOR
Intervention: Topical vitamin C after dermapen microneedling
Number of subjects: 20
Study 34191808 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based self-management program (video education and individual counseling by nurses)
Number of subjects: 30
Study 32185802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet orange aromatherapy
Number of subjects: 50
Study 32185802 — intervention group
Group type: COMPARATOR
Intervention: Calm breathing
Number of subjects: 50
Study 35100060 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime lighting condition
Number of subjects: 0
Study 35100060 — intervention group
Group type: COMPARATOR
Intervention: Nighttime lighting condition
Number of subjects: 0
Study 34529341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minoxidil 0.25 mg tablets
Number of subjects: 72
Study 34529341 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil 2% solution
Number of subjects: 72
Study 36272010 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-cleaning device (Y-brush®) for 5 seconds per jaw
Number of subjects: 20
Study 36272010 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush for a freely chosen time up to 4 minutes
Number of subjects: 20
Study 36272010 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-cleaning device (Y-brush®) for 15 seconds per jaw
Number of subjects: 20
Study 33958795 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG results
Number of subjects: 22641
Study 33958795 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 22641
Study 34261879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 63
Study 34787858 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC chemotherapy
Number of subjects: 150
Study 34787858 — intervention group
Group type: COMPARATOR
Intervention: Routine intravenous injection
Number of subjects: 150
Study 32098534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E blended HXLPE
Number of subjects: 199
Study 32098534 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE
Number of subjects: 199
Study 33012017 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (laser application twice a week, totaling 8 sessions, and gel placebo for 30 consecutive days)
Number of subjects: 34
Study 33012017 — intervention group
Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% (application three times a day for 30 consecutive days with laser placebo applied twice a week)
Number of subjects: 34
Study 33012017 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation and topical clobetasol 0.05%
Number of subjects: 34
Study 33012017 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Number of subjects: 34
Study 33248743 — intervention group
Group type: EXPERIMENTAL
Intervention: Training clinicians to increase TUD treatment
Number of subjects: 182
Study 33248743 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 182
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment assessment
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Care level assignment
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric diagnosis prevalence
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia diagnosis prevalence
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptom prevalence
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication usage
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care service utilization
Number of subjects: 402
Study 34253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Care related needs assessment
Number of subjects: 402
Study 35457632 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity program (twice a week for 8 weeks)
Number of subjects: 30
Study 35457632 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 34010843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg once daily)
Number of subjects: 190
Study 34010843 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg)
Number of subjects: 190
Study 34010843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190